



Press release

Cantargia AB
556791-6019
15 July 2016

Cantargia obtains a granted patent from USPTO concerning IL1RAP in solid tumors

The United States Patent and Trademark Office ("USPTO") has granted Cantargia AB's ("Cantargia") patent application concerning IL1RAP as a target molecule for antibody therapy of several solid tumor types. The granted patent follows the Notice of Allowance that was issued and communicated in June 2016.

The granted patent with number US 9,403,906 B1 planned to be published August 2, 2016, concerns Cantargias method to utilize IL1RAP as a target molecule for the treatment of several types of solid tumors. The patent provides protection until 2032 and covers treatment of several common forms of solid tumors, such as breast cancer, colon cancer, lung cancer and malignant melanoma.

"With the USPTO granting this patent, Cantargia has patent protection in the three major markets for pharmaceuticals – USA, Europe and Japan. The patent is important both for the development of our product candidate CAN04 as well as for our future patent portfolio" says Göran Forsberg, CEO.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Advisor: Sedermera Fondkommission

This information is information that Cantargia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 8:30 (CEST) on July 15, 2016.

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein "IL1RAP", in cancer stem cells in patients with leukaemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at <http://www.cantargia.com>.